Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma (NASDAQ: MDCX) has appointed Andrew Smith as Chief Operating Officer, effective June 30, 2025. Smith, 57, brings over three decades of experience in asset management and financial operations to the emerging growth company.
Key appointment details:
- Base salary: $325,000 annually
- Stock compensation: 100,000 options at $2.60 strike price, vesting quarterly over 5 years
- Prior experience includes CEO roles at SR Asset Management and leadership positions at Aberdeen Asset Management
- Educational background: Executive MBA from INSEAD and HND in Accounting from Glasgow College of Commerce
Smith initially joined as a consultant on May 27, 2025, and currently serves on the board of HazelTree Fund Services while advising Code Registry. The appointment involves no reportable related-party transactions or family relationships with other executives.
Medicus Pharma Ltd. (NASDAQ: MDCX) has filed Prospectus Supplement No. 6 to its April 10, 2025 S-1, attaching a Form 8-K dated June 17, 2025. The filing discloses the issuance of a third and final debenture to YA II PN, Ltd. (Yorkville) under the previously announced $5 million securities purchase agreement.
Key terms of the third debenture
- Principal amount: $2.5 million (remaining capacity under the agreement)
- Net proceeds to Medicus: $2.25 million
- Interest: 8.0% per annum, rising to 18.0% upon certain defaults
- Maturity: February 2, 2026
- Guaranteed by all company subsidiaries via a global guaranty agreement
This draws total funding under the Yorkville facility to its full $5 million principal, delivering $4.5 million in aggregate net cash since May 2025. The company characterises itself as an emerging growth company and warns investors of high risk, pointing to detailed risk factors in the base prospectus.
The common shares and public warrants (exercise price $4.64; expiry Nov 15 2029) remain listed on the Nasdaq Capital Market, last trading at $2.58 and $0.80, respectively, on June 18 2025.
Implications for investors: the completed financing strengthens short-term liquidity and funds ongoing operations, but adds leverage and exposes Medicus to higher coupon costs and covenant-linked default rate escalation. Guaranteeing subsidiaries also elevates secured creditor priority over equity holders.
Medicus Pharma Ltd. (NASDAQ: MDCX) filed an 8-K reporting that it has drawn the third and final tranche under the May 2, 2025 Securities Purchase Agreement with YA II PN, Ltd. (Yorkville). The company issued a $2.5 million principal debenture on June 17, 2025, delivering $2.25 million in net proceeds. Together with the two earlier debentures of $1.25 million each, Medicus has now issued the full $5 million aggregate principal authorized under the agreement, receiving $4.5 million in aggregate net cash.
The unsecured debentures are guaranteed by all subsidiaries via a global guaranty agreement. Key terms include:
- Coupon: 8.0% per annum, increasing to 18.0% if an event of default occurs.
- Maturity date: February 2, 2026 (≈ 7.5 months tenor remaining).
Item 2.03 confirms the debt constitutes a direct financial obligation. No equity conversion feature is disclosed, so the financing is presently purely debt-based, increasing leverage but avoiding immediate equity dilution. The filing does not state use of proceeds, financial covenants or repayment schedule beyond maturity.
Implications: The transaction immediately strengthens cash reserves, potentially funding pipeline or operating needs, but adds short-term debt bearing a relatively high interest rate and default step-up. Investors should assess Medicus’ liquidity profile, ability to service the 8% coupon and to refinance or repay $5 million by early 2026.